Drug Trial Radar · NCT07205081
Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Oct 22, 2025
Primary completion
Aug 13, 2026
Study completion Aug 13, 2026
Sponsor
- Lead sponsor
- Attovia Therapeutics IncIndustry
- Sponsor type
- Industry
- First posted
- Oct 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-3712 in healthy adults and patients with atopic dermatitis. The main questions it aims to answer are: What medical problems do participants have when taking ATTO-3712? How long does ATTO-3712 stay in the body after dosing? Researchers will compare ATTO-3712 to a placebo (a look-alike substance that contains no drug). Participants will be dosed with ATTO-3712 or a placebo, visit the clinic for checkups and tests, and keep a diary of their symptoms.
Conditions
- Normal Volunteers
- Atopic Dermatitis (AD)
- Atopic Eczema
- Atopic Eczema/Dermatitis (Non-Specific)
Interventions
ATTO-3712Drug
ATTO-3712
PlaceboDrug
Placebo preparation to match ATTO-3712 dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of AEsTime frame: 0-113 Days for SAD; 0-143 Days for MAD
- Incidence of laboratory abnormalitiesTime frame: 0-113 Days for SAD; 0-143 days for MAD
- Incidence of ECG abnormalitiesTime frame: 0-113 Days for SAD; 0-143 Days for MAD
- Incidence of vital sign abnormalitiesTime frame: 0-113 Days for SAD; 0-143 Days for MAD
Locations
17 sites in 3 countries. Site status is shown where the registry gives one.
Attovia Clinical Site 203
Encinitas, California
Attovia Clinical Site 209
Fountain Valley, California
Attovia Clinical Site 205
Huntington Beach, California
Attovia Clinical Site 204
Rocklin, California
Attovia Clinical Site 208
Coral Gables, Florida
Attovia Clinical Site 207
Sweetwater, Florida
Attovia Clinical Site 206
Indianapolis, Indiana
Attovia Clinical Site 202
Saint Joseph, Missouri
Attovia Clinical Site 210
New York, New York
Attovia Clinical Site 102
Peterborough, Ontario, Canada
Altasciences
Montreal, Quebec, Canada
Attovia Clinical Site 301
Auckland, Auckland, New Zealand
Attovia Clinical Site 306
Auckland, NZ, New Zealand
Attovia Clinical Site 304
Christchurch, NZ, New Zealand
Attovia Clinical Site 302
Hamilton, NZ, New Zealand
Attovia Clinical Site 303
Nelson, NZ, New Zealand
Attovia Clinical Site 305
Wellington, NZ, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.